

Expert Perspectives: Sequencing Treatments in Patients With HER2+ Metastatic Breast Cancer



WEDNESDAY, 14 MAY 2025 | 11:30–12:30 CEST | HYBRID

International Congress Center of the Munich Messe
Munich, Germany | Room 5

OVERVIEW

Join leading experts Drs Mueller, Criscitiello, and Borges for an interactive 1-hour symposium dedicated to the clinical decision-making process in the third-line setting for patients with HER2+ metastatic breast cancer (MBC). This session will delve into the complexities of treatment sequencing focusing on current treatment guidelines, the latest treatment data, and the value of real-world evidence to inform decision-making, including case-based scenarios for clinical practice implementation. Enhance your knowledge and clinical practice in patients with HER2+ MBC through this engaging and informative expert discussion.

AGENDA

Welcome and Introduction

Volkmar Mueller, MD

Where Are We Today: Understanding the Evolving Treatment Landscape of HER2+ MBC

Carmen Criscitiello, MD, PhD

How Do You Treat? Expert Insights Into Clinical Decision-Making in 3L HER2+ MBC

Virginia Borges, MD

Expert Panel Q&A on Clinical Decision-Making in 3L HER2+ MBC

All faculty

Looking Into the Future of HER2+ MBC

Volkmar Mueller, MD

Panel Discussion and Audience Q&A

All faculty

Closing Remarks

Volkmar Mueller, MD

FACULTY



Volkmar Mueller, MD [CHAIR]

Department of Gynecology and University Breast Center
University Medical Center Hamburg-Eppendorf
Hamburg, Germany



Carmen Criscitiello, MD, PhD

University of Milan
European Institute of Oncology (IEO), IRCCS
Milan, Italy



Virginia Borges, MD

UC Health Cancer Care
Anschutz Medical Campus
University of Colorado Cancer Center
Aurora, Colorado, USA